Company intelligence / Profile preview

Sixera Pharma

Ownership: Private
Development stage: Preclinical

Overview

Sixera Pharma’s lead compound SXR1096 is a first-in-class small molecule inhibitor of kallikreins 5, 7, and 14. It is formulated as a topical cream for the treatment of Netherton syndrome. The company has initiated its first clinical trial with SXR1096 in Europe and received Rare Pediatric Disease Designation from the FDA. Clinical development is ongoing; no efficacy results have been published yet but preclinical data support its mechanism targeting overactive skin proteases in this rare genetic disorder.

Therapeutic areas: Dermatology
Modalities: Small moleculeTopical cream formulation
Industry: Biotech

Drug pipeline

1 asset

SXR1096

Partnerships

No major pharmaceutical partnerships disclosed; development involves academic and industrial collaborations.

Beyond the preview

Go deeper on Sixera Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sixera Pharma.

Explore the full profile